Overview

Safety and Efficacy of P-188 NF in DMD Patients

Status:
Suspended

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

This is an open-label study to evaluate the safety, tolerability and efficacy of daily, subcutaneous dosing with P-188 NF (Carmeseal-MD™) in non-ambulatory boys with Duchenne Muscular Dystrophy (DMD). This study will determine if continuous treatment with Carmeseal-MD™ can maintain or improve pulmonary function, and skeletal and cardiac muscle function, compared to baseline, in boys 12-25 years of age.

Phase:

Phase 2

Details

Lead Sponsor:

Phrixus Pharmaceuticals, Inc.

Collaborator:

Charley's Fund